Raphael Pharmaceutical (RAPH) Income from Continuing Operations (2020 - 2024)
Raphael Pharmaceutical's (RAPH) quarterly Income from Continuing Operations came in at 394000.0 in Q4 2024, down 394.03% year-on-year from 134000.0 in Q1 2024, and down 23.51% quarter-over-quarter from 319000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) Income from Continuing Operations (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has disclosed Income from Continuing Operations across 5 years of filings, most recently posting 394000.0 for Q4 2024.
- Income from Continuing Operations for Q4 2024 came in at 394000.0, down 394.03% year-over-year; the trailing twelve-month figure through Dec 2024 was 1509000.0 (down 18.63% YoY), and the FY2025 annual result was 1245000.0, up 17.5% from the prior year.
- Income from Continuing Operations came in at 394000.0 for Q4 2024 at Raphael Pharmaceutical, down from 319000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 134000.0 in Q4 2023 to a low of 1426000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 389500.0 (2021), against an average of 454944.44.
- Across the five-year window, Income from Continuing Operations jumped 112.14% in 2023 and sank 394.03% in 2024, its largest moves.
- Raphael Pharmaceutical's Income from Continuing Operations stood at 227000.0 in 2020, then tumbled by 152.86% to 574000.0 in 2021, then slumped by 92.33% to 1104000.0 in 2022, then jumped by 112.14% to 134000.0 in 2023, then tumbled by 394.03% to 394000.0 in 2024.
- The last three Income from Continuing Operations figures came in at 394000.0 (Q4 2024), 319000.0 (Q3 2024), and 249000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Raphael Pharmaceutical | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -394,000.00 |
| Sep 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -547,000.00 |
| Dec 31, 2023 | 134,000.00 |
| Sep 30, 2023 | -729,000.00 |
| Jun 30, 2023 | -419,000.00 |
| Mar 31, 2023 | -258,000.00 |
| Dec 31, 2022 | -1.10 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -612,000.00 |
| Mar 31, 2022 | -175,000.00 |
| Dec 31, 2021 | -574,000.00 |
| Sep 30, 2021 | -418,000.00 |
| Jun 30, 2021 | -385,000.00 |
| Mar 31, 2021 | -252,000.00 |
| Dec 31, 2020 | -227,000.00 |
| Sep 30, 2020 | -235,000.00 |